Dengue Vaccines Market Size, Share, Growth, and Industry Analysis, By Type (CYD-TDV,Tak-003), By Application (Hospitals,Government Institutes,Non-Governmental Organizations (NGOs)), Regional Insights and Forecast to 2035

Dengue Vaccines Market Overview

The global Dengue Vaccines Market size is projected to grow from USD 776.62 million in 2026 to USD 911.52 million in 2027, reaching USD 2797.04 million by 2035, expanding at a CAGR of 17.37% during the forecast period.

The Dengue Vaccines Market Market comprises immunization products targeting four dengue virus serotypes (DENV-1 to DENV-4), intended for use in endemic and travel-risk populations. In 2024, only two dengue vaccines—CYD-TDV (Dengvaxia) and TAK-003 (Qdenga)—were licensed globally. TAK-003 gained WHO prequalification in May 2024, becoming the second dengue vaccine to be so certified. Clinical trials have enrolled over 27,000 participants in TAK-003 development. In CYD-TDV Phase III trials such as CYD14 and CYD15, vaccine efficacy estimates ranged from ~56.5 % to 60.8 % versus symptomatic dengue in various serotypes. The dengue vaccines market is tracked across ~90 endemic countries and ~15 travel destination nations in B2B procurement channels. The Dengue Vaccines Market Report assesses government immunization programs, regulatory adoption rates, and forecast demand in high-risk zones.

In the United States, dengue vaccination is not widely deployed due to low endemic incidence, but research and policy interest exist. Takeda withdrew its U.S. Biologics License Application (BLA) for TAK-003 in July 2023, citing review timing issues. Nevertheless, U.S. regulatory bodies track dengue vaccine clinical development in ~5 U.S. trials. The CDC evaluated CYD-TDV using GRADE frameworks in multiple populations. The U.S. travel vaccine market accounts for ~5 % of global dengue vaccine procurement, targeting travelers to Latin America and Asia. Several U.S. public health agencies conduct serosurveys across ~20 southern states to assess baseline dengue exposure rates (seropositivity ~10–15 %). These surveillance data feed into U.S. vaccine policy modeling and Dengue Vaccines Market Analysis projections.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Roughly 70 % of demand stems from heightened dengue incidence in tropical and subtropical regions.
• Major Market Restraint: Around 30 % of potential uptake is limited by safety concerns in seronegative populations.
• Emerging Trends: Nearly 40 % of new vaccine development pipelines focus on next-generation dengue vaccine candidates.
• Regional Leadership: Asia-Pacific and Latin America combined account for ~60 % of global vaccine demand.
• Competitive Landscape: The top two vaccine developers control ~90 % of licensed dengue vaccine output.
• Market Segmentation: Approximately 100 % of deployed vaccines are live attenuated formulations currently.
• Recent Development: In 2024, WHO prequalified TAK-003, adding a second vaccine to global procurement lists.

Dengue Vaccines Market Latest Trends

The Dengue Vaccines Market is evolving with improvements in vaccine design, regulatory expansion, and public health adoption. In 2024, WHO prequalified TAK-003, enabling its purchase by UN agencies across ~40 countries. In clinical studies, TAK-003 showed ~84.1 % efficacy against hospitalized dengue over 4.5 years in endemic settings. Early protection onset data indicate ~82.1 % efficacy within three months after the first dose, with onset around 14 days in trials enrolling ~4,000 children. CYD-TDV long-term data from 4-year follow-ups show symptomatic efficacy of ~56.5 % to ~60.8 % in children 2–17 years old, with differential serotype performance. Several countries in Asia have initiated rollout plans: Takeda plans to launch TAK-003 in India via a manufacturing tie-up with Biological E. Regulatory reviews for TAK-003 are ongoing in ~20 countries.

Dengue Vaccines Market Dynamics

DRIVER

"Rising dengue burden and public health demand"

Dengue incidence has escalated globally: from ~500,000 reported cases in 2000 to over 5 million in 2019, with thousands of deaths annually. In 2023, reported dengue cases exceeded 5 million across 129 countries. Over 80 % of cases occur in Asia and Latin America combined. Governments in Brazil, India, Philippines, and Indonesia record outbreaks surpassing 700,000 cases per year. As dengue becomes endemic in urban and periurban areas, demand for vaccines in ~70 high-burden countries intensifies. Public health agencies are budgeting to immunize children aged 9–16 over multi-year campaigns covering tens of millions per cycle. The Dengue Vaccines Market Analysis shows over 60 % of procurement tends to be government or institutional purchases.

Market Restraints

"Safety risks and serostatus constraints"

CYD-TDV is contraindicated in seronegative children under 9 due to risk of enhanced disease; thus ~20 % potential population is excluded. Safety concerns are major hurdles: in CYD14/15 trials breakthrough hospitalizations occurred in some vaccinated individuals over 4–5 years. Approximately 30 % of uptake is suppressed by concerns over long-term safety in seronegative recipients. TAK-003 showed higher safety balance, but still about 23.2 % of participants reported medically attended adverse events. Clinical development included ~27,000 participants, with death incidence <0.1 % in both vaccine and placebo groups. Regulatory agencies demand long-term surveillance, often 5–10 years post-licensure. These constraints slow adoption, especially in countries needing pre-vaccination serological screening.

Market Opportunities

"Second vaccines, heterologous boosters, broader age groups"

TAK-003’s WHO prequalification opens procurement potential in 40+ countries immediately. Countries that previously had only CYD-TDV will now have an alternative, expanding coverage. Booster or heterologous prime-boost strategies are being studied: recombinant subunit candidate V180 has entered trials as booster to live-attenuated vaccines. More than 20 new dengue vaccine candidates are in Phase I/II, including inactivated and mRNA platforms. Governments in ~15 endemic nations plan immunization campaigns reaching 20–40 million children per cycle. Manufacturers are planning local production in India, Latin America, Southeast Asia, aiming to reduce import dependency in ~30 countries. These incremental adoption steps constitute major strategic opportunities in Dengue Vaccines Market Opportunities.

Market Challenges

"Clinical complexity, heterogeneity, cost and distribution"

Vaccine development is challenged by dengue’s four serotypes, antibody-dependent enhancement risk, and varying serostatus in populations. Efficacy fluctuates by serotype: CYD-TDV protection against DENV2 and DENV4 was lower. TAK-003 shows more balanced titers but differential neutralization. Neutralizing antibody bridging work involves complex assays like complement-fixing antibody tests in Luminex assays. Logistics pose challenges: vaccines require cold chain (2–8 °C) with minimal wastage; many endemic regions have limited refrigeration capacity. Cost per vaccine dose may restrict uptake in low-income countries. Achieving high coverage (≥80 %) across multi-dose schedules is difficult in rural/remote regions. Surveillance and tracking in post-licensure demand investments; many countries only cover ~50 % of dengue case surveillance.

Dengue Vaccines Market Segmentation

The Dengue Vaccines Market Market is segmented by type (CYD-TDV, TAK-003) and application (Hospitals, Government Institutes, NGOs). CYD-TDV and TAK-003 dominate licensing activity; applications span immunization campaigns and institutional deployment. Market segmentation aids in modeling procurement shares and adoption timelines across public and private health systems.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

CYD-TDV: CYD-TDV, marketed as Dengvaxia by Sanofi, is a live attenuated chimeric vaccine that protects against all four dengue virus serotypes. Approved in 2015, it has been used in more than 20 endemic countries. Clinical data from trials CYD14 and CYD15 showed efficacy between 56.5 and 60.8 percent among children aged 2 to 17 years. Approximately 1.2 million adolescents in the Philippines and 3 million individuals in Brazil have received at least one dose under national programs. The vaccine is indicated only for seropositive individuals aged 9 to 45 years, as seronegative populations show an increased risk of severe dengue post-vaccination. CYD-TDV continues to be part of targeted immunization campaigns tracked in the Dengue Vaccines Market Industry Report.

Tak-003: Tak-003, also known as Qdenga, is a tetravalent live attenuated dengue vaccine developed by Takeda Pharmaceuticals and prequalified by the World Health Organization in May 2024. It demonstrated 84.1 percent efficacy against hospitalized dengue and 61.2 percent efficacy against virologically confirmed dengue over a 4.5-year trial period involving more than 27,000 participants. Early onset protection occurred within 14 days of the first dose, with 82.1 percent efficacy recorded within three months. Tak-003 is approved for individuals aged 4 and above in over 40 countries. The Dengue Vaccines Market Market Forecast identifies Tak-003 as the leading candidate for mass immunization programs in Asia-Pacific, Latin America, and parts of Africa.

BY APPLICATION

Hospitals: Hospitals account for about 15 percent of global dengue vaccine administration. Over 1,000 large healthcare institutions across Latin America, Southeast Asia, and India deliver dengue vaccines through outpatient clinics and pediatric wards. Hospital-based vaccination centers maintain cold chain capacity for 10-dose vials at 2 to 8 degrees Celsius. Approximately 5 percent of annual vaccine distribution targets travelers and hospital staff in non-endemic regions. Hospital immunization programs cover nearly 10 million children aged 9 to 16 annually and provide the foundation for data reporting within the Dengue Vaccines Market Analysis framework.

Government Institutes: Government Institutes are the largest end users, managing roughly 70 percent of dengue vaccine deployment. National health ministries in Brazil, Thailand, and Indonesia conduct mass campaigns reaching over 20 million children annually. About 80 percent of global serostatus screening is coordinated through public health agencies prior to vaccination. More than 40 endemic nations maintain dengue immunization as part of their public health portfolios. Government-driven programs oversee procurement, supply logistics, and monitoring of vaccine efficacy data that shape the Dengue Vaccines Market Market Outlook for the next decade.

Non-Governmental Organizations (NGOs): NGOs represent about 10 percent of global dengue vaccine distribution, particularly in underserved and rural areas. Approximately 200 non-profit projects across Asia and Latin America facilitated immunization for 500,000 children in 2024. NGOs collaborate with ministries of health and WHO to provide mobile vaccination clinics and manage outreach logistics in low-resource regions. Their programs allocate around 15 percent of their budget to portable refrigeration and training staff. NGO involvement accelerates vaccine coverage in countries with limited public health infrastructure, a factor increasingly highlighted in Dengue Vaccines Market Market Opportunities assessments.

Dengue Vaccines Market Regional Outlook

Global dengue vaccine deployment is regionally skewed: Asia-Pacific and Latin America dominate with ~60 % combined uptake, followed by Africa, the Middle East, and limited deployment in North America and Europe.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America accounts for minimal routine dengue vaccine use due to low endemicity. However, travel vaccine demand is rising: approximately 5 % of global vaccine doses are purchased for travelers to Latin America and Asia. U.S. clinical trial sites number ~5 for dengue vaccines. The CDC and non-travel health providers in ~15 U.S. states issue dengue vaccine advisories. The U.S. has withdrawn the BLA for TAK-003, but still supports surveillance in ~10 southern states for vaccine policy modeling.

EUROPE

Europe’s dengue vaccine adoption is modest. Regulatory approvals include EMA acceptance of TAK-003 for eligible travelers. In EU countries, ~2 million travelers annually to dengue zones are potential vaccine recipients. European public health bodies are evaluating vaccine inclusion in travel health guidelines. Clinical trials in Europe enroll ~1,000 participants for long-term data. European NGOs assist vaccine access in returning travelers and expatriates.

ASIA-PACIFIC

Asia-Pacific is the most active region. Countries such as Indonesia, Thailand, Philippines, Malaysia, and Vietnam have high dengue incidence rates. Indonesia is preparing to roll out TAK-003 across ~30 provinces. The Philippines previously used CYD-TDV in campaigns reaching over 1 million adolescents. In 2024, ~40 countries authorized TAK-003, many in Asia-Pacific. Several nations plan to vaccinate 10 to 20 million children over successive campaigns. Local manufacturing in India and Vietnam is underway to meet regional demand.

MIDDLE EAST & AFRICA

In the Middle East & Africa, dengue incidence is lower but rising in some zones. Select nations in the Arabian Peninsula and East Africa are evaluating vaccine adoption. NGO-supported pilot immunization has occurred in ~5 African countries in endemic zones. Vaccine procurement in these regions is often via global health agencies. Dengue surveillance in ~20 countries feeds eligibility for vaccine programs.

List of Top Dengue Vaccines Companies

• Takeda Pharmaceutical
• Sanofi

Top two companies with the highest market share:

• Takeda Pharmaceutical
• Sanofi

Investment Analysis and Opportunities

Investment in the Dengue Vaccines Market is increasingly directed to next-generation vaccine development, manufacturing scale-up, and immunization programs. In 2024, vaccine developers announced ~USD 40 million in R&D funding across ~25 pipeline projects. Governments in ~15 endemic nations have allocated budgets to vaccinate 10 to 20 million adolescents over 5 years. Partnership models are emerging: Takeda is engaging in a tie-up with Biological E in India for local production and tiered pricing. International agencies now deploy ~USD 10 million annually to subsidize vaccination in low-income countries. Private health systems in travel medicine markets purchase ~5 % of total vaccine doses.

New Product Development

Innovation focuses on improving safety, broad serotype coverage, and alternative platforms. Several dengue vaccine candidates are in Phase II or exploratory development using recombinant subunit, inactivated, and nucleic acid platforms. Example: the V180 recombinant envelope subunit vaccine is studied as booster to live attenuated vaccines in ~300 participants. mRNA/dengue platform projects are in preclinical phase (≥10 candidates globally). Some next-gen candidates aim to deliver tetravalent coverage with two-dose regimens or single-dose formats. Engineering of non-enhancing antigen constructs is in progress to reduce antibody-dependent enhancement risk. Clinical bridging studies evaluate complement-fixing antibody assays in ~2,000 samples to compare immune responses with standard live vaccines. Vaccine delivery innovations include micro-needle patches and thermostable formulations able to survive 2 weeks at 40 °C. The Dengue Vaccines Market Industry Report highlights these as key differentiators to drive wider adoption.

Five Recent Developments

• In May 2024, WHO prequalified TAK-003, making it available for procurement by UNICEF and PAHO.
• In July 2023, Takeda withdrew the U.S. BLA for TAK-003 due to unresolved review questions.
• In 2025, Takeda announced partnership with Biological E to manufacture TAK-003 in India for local immunization.
• Over 27,000 participants were included in TAK-003 safety trials; eighteen deaths occurred during development (<0.1 % incidence) with none attributed to vaccine.
• In 2024, early onset protection data revealed ~82.1 % efficacy within first three months post first dose, with onset of ~14 days in trial populations.

Report Coverage

The Dengue Vaccines Market Report addresses global demand, licensing status, coverage adoption, and pipeline development for dengue immunization. It segments by vaccine type (currently CYD-TDV and TAK-003) and application channels (hospitals, government institutes, NGOs). Regional analyses span North America, Europe, Asia-Pacific, and Middle East & Africa, with share estimates and rollout prospects. Competitive profiling covers Sanofi (CYD-TDV) and Takeda (TAK-003), their clinical pipelines, licensing status, and strategic partnerships. The report tracks over 40 pipeline candidates in preclinical and Phase I/II stages. Projected procurement cycles, supply constraints, cold chain logistics, and disease surveillance systems are mapped across ~70 endemic countries.

Dengue Vaccines Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 776.62 Million in 2026
Market Size Value By	USD 2797.04 Million by 2035
Growth Rate	CAGR of 17.37% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : CYD-TDV Tak-003 By Application : Hospitals Government Institutes Non-Governmental Organizations (NGOs)
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample